KDM4B and breast cancer: A novel KDM4 inhibitor, NCDM-32B, has shown some utility in the treatment of a subset of aggressive breast cancers, in which it functions by disrupting several key pathways driving cell proliferation and transformation in breast cancer through inhibition of KDM4B expression (Ye et al., 2015).